How have XBIT shares performed in 2024?

XBiotech's stock was trading at $4.00 at the beginning of 2024. Since then, XBIT stock has increased by 101.0% and is now trading at $8.04. View the best growth stocks for 2024 here .

When is XBiotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our XBIT earnings forecast .

How were XBiotech's earnings last quarter?

XBiotech Inc. (NASDAQ:XBIT) announced its quarterly earnings results on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter.

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com . John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU) , Gilead Sciences (GILD) , Advanced Micro Devices (AMD) , Walt Disney (DIS) , Cisco Systems (CSCO) , NVIDIA (NVDA) , Inovio Pharmaceuticals (INO) , Intel (INTC) , Pfizer (PFE) and Block (SQ) .

When did XBiotech IPO?

XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XBIT

XBiotech (XBIT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free XBIT Stock Alerts

$8.04

+0.13 (+1.64%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.51
▼
$8.34
50-Day Range: $5.78
▼
$9.89
52-Week Range: $3.05
▼
$9.96

Volume: 76,231 shs
Average Volume: 61,499 shs
Market Capitalization: $244.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get XBiotech alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About XBiotech Stock (NASDAQ:XBIT)

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBIT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XBIT Stock News Headlines

April 18, 2024 | americanbankingnews.com

XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $7.19

March 20, 2024 | finance.yahoo.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 18, 2024 | investorplace.com

XBIT Stock Earnings: XBiotech Reported Results for Q4 2023

March 8, 2024 | finance.yahoo.com

The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech

February 17, 2024 | finance.yahoo.com

XBIT Mar 2024 5.000 call

January 18, 2024 | morningstar.com

XBiotech Inc XBIT

January 8, 2024 | bizjournals.com

A top Austin biopharmaceutical company is doubling down on its Austin campus

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 4, 2024 | finance.yahoo.com

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

December 15, 2023 | msn.com

ARCT, EHTH and CRTO are among after hour movers

December 5, 2023 | finance.yahoo.com

Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth

November 14, 2023 | finanznachrichten.de

XBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

November 14, 2023 | finance.yahoo.com

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

September 26, 2023 | finance.yahoo.com

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

August 8, 2023 | finanznachrichten.de

XBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

August 8, 2023 | finance.yahoo.com

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

June 30, 2023 | thestreet.com

XBiotech Cancer Drug Survival Claim Falls Apart Under Scrutiny

May 23, 2023 | finanznachrichten.de

XBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 22, 2023 | finance.yahoo.com

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 17, 2023 | finanznachrichten.de

XBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

May 17, 2023 | finance.yahoo.com

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

April 17, 2023 | finanznachrichten.de

XBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

April 17, 2023 | finance.yahoo.com

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

April 9, 2023 | finance.yahoo.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders

February 15, 2023 | finance.yahoo.com

The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable

November 11, 2022 | finance.yahoo.com

XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

See More Headlines

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XBIT
CUSIP: N/A
CIK: 1626878
Web: www.xbiotech.com
Phone: (512) 386-2900
Fax: 512-386-5505
Employees: 82
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,560,000.00
Net Margins: N/A
Pretax Margin: -7,401.67%
Return on Equity: -10.82%
Return on Assets: -10.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 33.07
Quick Ratio: 33.07

Sales & Book Value

Annual Sales: $4.01 million
Price / Sales: 61.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.19 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 30,450,000
Free Float: 21,803,000
Market Cap: $244.82 million
Optionable: Optionable
Beta: 1.45

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. John Simard (Age 62)
Founder, President, CEO & Chairman
Comp: $4.67M
Dr. Sushma Shivaswamy Ph.D. (Age 46)
Chief Scientific Officer
Comp: $381.24k
Ms. Angela Hu (Age 40)
Director of Finance, Principal Financial & Accounting Officer and Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

XBIT Stock Analysis - Frequently Asked Questions

How have XBIT shares performed in 2024?: XBiotech's stock was trading at $4.00 at the beginning of 2024. Since then, XBIT stock has increased by 101.0% and is now trading at $8.04.
View the best growth stocks for 2024 here.
When is XBiotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our XBIT earnings forecast.
How were XBiotech's earnings last quarter?: XBiotech Inc. (NASDAQ:XBIT) announced its quarterly earnings results on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter.
What is John Simard's approval rating as XBiotech's CEO?: 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).
When did XBiotech IPO?: XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.
How do I buy shares of XBiotech?: Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XBIT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial